Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Overview of attention for article published in The Journal of Headache and Pain, May 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 89 Dimensions

Readers on

mendeley: 52 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 5,787 followers.

RT @EHF_Official: The GARLIT study is the first multicenter study proving the efficacy and safety of galcanezumab in real-life. The treatme…

18 May 2021

Reply Repost Favourite

This is great for our long suffering difficult to treat migraine patients. Thankfully we have this already available for Leeds patients. @LTHTNEURO

18 May 2021

Reply Repost Favourite

The GARLIT study is the first multicenter study proving the efficacy and safety of galcanezumab in real-life. The treatment extensively reduced MHDs and MMDs in hard-to-treat patients with HFEM or CM. Read more here https://t.co/dvS5j9v1RD https://t.co/3iM

18 May 2021

Reply Repost Favourite

RT @NeuroPsychBMC: Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter pro…

05 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.